[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Tianjin First Central Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":188},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,48,71,94,120,143,168],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100651405","phase-2-nk-cells-plus-ici-for-sclc-maintenance-100651405",false,"NCT07759856","NK Cells Plus ICI for SCLC Maintenance","A Randomized, Controlled, Open and Exploratory Clinical Trial of Immunization Combined With Allogeneic NK Cells in the Immune Maintenance Stage After First-line Treatment of Extensive Small Cell Lung Cancer","NK-ICI-SCLC","Inclusion Criteria:\n\n* 1: Male or female, aged 18 years or above\n\n  2: ECOG score 0-2\n\n  3: metastatic or extensive-stage small cell lung cancer (SCLC) confirmed by histology or cytology, followed by 4 cycles of platinum-based doublet-chemotherapy with at least 2 cycles of immune checkpoint inhibitor plus chemotherapy. And stable disease (SD), partial response (PR), or complete response (CR) as assessed by imaging (RECIST1.1 criteria) after the last treatment. (The checkpoint inhibitors used were those recommended by the NCCN, ESMO, and CSCO guidelines for extensivestage SCLC, including but not limited to: Duvalumab, atezolizumab, slulizumab, adbelimumab, toripalimab, etc.)\n\n  4: After standard concurrent chemoradiotherapy, LS-SCLC could be enrolled in this study if sensitive relapse (relapse more than 6 months after the end of first-line treatment) progressed to extensive-stage (Ed) and met the inclusion criteria No.3;\n\n  5: At least 4 weeks after major surgery or trauma, and the wound must be completely healed; At least 1 week after minor surgical procedures or trauma (e.g., tissue biopsy or fine-needle aspiration);\n\n  6: Objective measurable lesions according to RECIST 1.1 criteria;\n\n  7: predicted survival time ≥1 year;\n\n  8: bone marrow function: ANC≥1.5×109\u002FL, HB≥70 g\u002FL (blood transfusion allowed), PLT≥80×109\u002FL;\n\n  9: Liver function: ALT≤3×ULN, AST≤3×ULN, TBIL≤2×ULN (patients with liver metastasis ALT≤5×ULN, AST≤5×ULN, TBIL≤2×ULN) Child-Pugh score ≤7; Renal function: uric acid \\\u003C500 μmol\u002FL, serum creatinine \\\u003C1.7 mg\u002FdL, proteinuria ≤2+ or ≤2g\u002F24h, glomerular filtration rate (GFR) ≥60 ml\u002Fmin\u002F1.73m2;\n\n  10: no history of autoimmune diseases or current autoimmune diseases;\n\n  11: The subjects voluntarily participated in the study, signed the informed consent form, communicated well with the investigators, and completed the study in accordance with the protocol.\n\nExclusion Criteria:\n\n* 1:Participate in other clinical trials or use other research drugs or equipment within 4 weeks of the first treatment.\n\n  2: During the screening period and previous imaging evaluation, active or untreated CNS metastasis was found by CT scanning or MRI. Patients with asymptomatic CNS metastasis who had been treated in the past can participate in this study as long as they meet all the following criteria: corticosteroids are not needed to treat CNS diseases, and imaging examination has not found any progress from the end of CNS directional treatment to the screening period。 If new asymptomatic CNS metastases are found in patients during the screening period, they must undergo radiotherapy and\u002For CNS metastasis surgery\n\n  3: The effusion in the third space with clinical symptoms needs repeated drainage (for example, less than once every four weeks), such as pericardial effusion, pleural effusion and peritoneal effusion that are still uncontrollable after pumping or other treatments\n\n  4: Live vaccine was inoculated within 30 days before the first administration of the study drug. Live vaccines include but are not limited to measles, mumps, minute needle, chickenpox\u002Fherpes zoster, rabies, BCG, typhoid vaccine, etc. Seasonal influenza vaccine for injection is generally inactivated virus vaccine, which is allowed to be used.\n\n  5: The patient is known to have other malignant tumors, which are progressing or need active treatment in the past 3 years (except for in situ cancer or localized prostate cancer supplemented by PSA test)\n\n  6: Received major surgery, open surgical biopsy or severe traumatic injury 28 days before joining the group.\n\n  7: Clinically related or preexisting interstitial lung disease\n\n  8: Severe unhealed wound, ulcer or fracture\n\n  9: Suffering from autoimmune diseases requiring systemic treatment in the past 2 years\n\n  10: Unstable systemic concomitant diseases (active infection, moderate and severe chronic obstructive pulmonary disease, poorly controlled hypertension, unstable angina pectoris, congestive heart failure, myocardial infarction, cerebrovascular accident, pulmonary embolism or untreated history of Grade 3 deep vein thrombosis (DVT) within 6 months, serious mental disorder requiring drug control, liver, kidney or other metabolic diseases, neuropsychiatric diseases such as Alzheimer's disease).\n\n  11: According to the judgment of the researcher, there are patients with accompanying diseases that seriously endanger the safety of patients or affect the completion of the study.","ALL","18 Years",{"count":20,"type":21},42,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This research study is designed for patients with extensive-stage small cell lung cancer (ES-SCLC) who have already received four cycles of standard chemotherapy, with at least two cycles combined with immunotherapy, and have achieved disease control (stable disease, partial response, or complete response) at their last efficacy evaluation.\n\nIn this study, participants will be randomly assigned to one of two groups:\n\nGroup A will receive standard immunotherapy plus 1 to 3 courses of allogeneic natural killer (NK) cell therapy. Each course consists of six NK cell infusions given over 28 days.\n\nGroup B will receive standard immunotherapy alone. All participants will continue treatment until their disease progresses or they experience unacceptable side effects. The immunotherapy agents used in this study are those recommended by major international and national clinical guidelines for extensive-stage SCLC, including but not limited to durvalumab, atezolizumab, serplulimab, and adebrelimab.\n\nThe purpose of this study is to evaluate whether adding NK cell therapy to standard immunotherapy can provide additional benefits for patients with extensive-stage SCLC who have responded well to initial treatment.",[27],"Small Cell Lung Cancer",[29,30,31,32,33,34],"Extensive-Stage Small Cell Lung Cancer","Immunotherapy","Allogeneic NK Cells","Natural Killer Cells","Maintenance Therapy","Randomized Controlled Trial","RECRUITING","2026-08-06",{"date":38,"type":39},"2026-08-12","ACTUAL",{"date":41,"type":21},"2026-08",{"date":43,"type":21},"2029-08",{"name":45,"class":46},"Tianjin First Central Hospital","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100647945","investigator-initiated-study-of-bbm-c101-injection-in-subjects-with-hpv1618-infection-100647945","NCT07714577","Investigator-Initiated Study of BBM-C101 Injection in Subjects With HPV16\u002F18 Infection","A Investigator-Initiated Exploratory Clinical Study to Evaluate the Safety, Tolerability and Efficacy of Injection BBM-C101 in Subjects With HPV16\u002F18 Infection","Inclusion Criteria:\n\n1. Confirmed HPV16 and\u002For HPV18 infection of the cervix, vulva, vagina or anus lasting for more than 1 year at screening; patients who decline surgical treatment or have failed prior pharmaceutical therapy (e.g., 5% imiquimod cream, 1% cidofovir gel);\n2. Histopathological diagnosis of ≤ Grade 2 CIN, VIN, VAIN or AIN via colposcopy or anoscopy at a local hospital (lesion specimens obtained within 3 weeks prior to the first study treatment); willing to provide biological samples throughout the study;\n\n4.Screening electrocardiogram shows normal findings or no clinically significant abnormalities as judged by the investigator; 5.Fertile eligible participants must agree to use reliable contraceptive methods together with their partners during the trial and for at least 1 year after the last administration (hormonal contraceptives, barrier methods, or abstinence); female participants of childbearing potential must have a negative serum pregnancy test within 7 days before enrollment;\n\nExclusion Criteria:\n\n1. Cytology results obtained during screening showing any of the following: adenocarcinoma in situ (AIS), atypical glandular cells favor neoplasia (AGC-FN), invasive carcinoma, etc.\n2. Received disease-related treatments within 4 weeks prior to the first vaccination, including pharmaceutical therapy (e.g., immunomodulators, fluorouracil ointment, recombinant human interleukin-2 injection), physical therapy (cryotherapy, laser therapy, photodynamic therapy), or surgical treatment.\n3. Prior administration of any therapeutic HPV vaccine (licensed prophylactic HPV vaccines are permitted).\n4. Received any vaccine within 4 weeks or 2 weeks prior to the first vaccination.\n5. Past or current diagnosis of other malignant tumors (exceptions: completely treated and cured ductal carcinoma in situ of breast, basal cell carcinoma of the skin, superficial bladder tumors, or any malignancy cured for more than 5 years with no evidence of recurrence prior to study entry).\n6. Active autoimmune disease or medical history of autoimmune disorders.\n7. Other immunocompromised conditions, including subjects receiving immunostimulants or immunosuppressants within 3 months (oral or intravenous administration lasting more than 14 consecutive days); subjects receiving whole blood, plasma or immunoglobulin therapy within 1 month; subjects with clinically diagnosed impaired or deficient immune function; or functional asplenia or splenectomy due to any cause.\n8. Severe allergic history, history of allergic disorders, or allergic diathesis.\n9. Participation in another clinical trial within 4 weeks prior to the first study vaccine administration.\n10. Underwent major surgery or sustained significant trauma within 4 weeks prior to the first study vaccine administration.\n11. Active hepatitis B (HBV viral load \\>1000 copies\u002FmL or 200 IU\u002FmL; prophylactic antiviral therapy other than interferon is allowed); hepatitis C virus infection.\n12. History of immunodeficiency or positive HIV antibody test result.\n13. Systemic active bacterial, fungal or viral infection (defined as infection requiring intravenous antibacterial, antifungal or antiviral agents).\n14. Long-term (≥7 consecutive days) systemic glucocorticoid therapy (prednisone ≥20 mg\u002Fday or equivalent dose) or other immunosuppressants (short-term glucocorticoids for prophylaxis and topical glucocorticoids including ophthalmic, intra-articular, intranasal and inhaled formulations are permitted). Current or planned use of anti-rheumatic or immunomodulatory agents such as azathioprine, cyclophosphamide, cyclosporine, methotrexate and TNF-α inhibitors (infliximab, adalimumab, etanercept, etc.).\n15. History of solid organ transplantation or bone marrow transplantation.\n16. Pregnant or breastfeeding female subjects.\n17. Any other conditions that may interfere with study procedures, compromise the subject's maximum benefit from participation, or confound study outcomes, including history of psychiatric disorders, drug addiction or substance abuse, or any other clinically significant unstable medical conditions (e.g., chronic renal failure).",{"count":56,"type":21},200,[58],"NA","This is a single-arm, single-center, open-label Investigator-Initiated Trial (IIT) designed to evaluate the safety and efficacy of BBM-C101 Injection in subjects with HPV16\u002F18 infection and histopathologically confirmed ≤ Grade 2 CIN, VIN, VAIN or AIN via colposcopy or anoscopy, with a planned enrollment of 200 subjects. The study consists of three phases: a 4-week screening period, a 52-week treatment\u002Ffollow-up period, and a 52-week long-term follow-up period. Safety will be assessed based on vital signs, physical examinations, laboratory tests, as well as the number and severity of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) occurring throughout the study.",[61],"HPV16\u002F18 Positive","NOT_YET_RECRUITING","2026-07-15",{"date":65,"type":39},"2026-07-20",{"date":67,"type":21},"2026-07-30",{"date":69,"type":21},"2031-08-01",{"name":45,"class":46},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":4},"100647377","phase-2-nimotuzumab-combined-with-the-stupp-regimen-for-postoperative-residual-glioblastoma-100647377","NCT07707973","Nimotuzumab Combined With the Stupp Regimen for Postoperative Residual Glioblastoma","A Single-arm, Phase II Study of Nimotuzumab Combined With the Stupp Regimen for Postoperative Residual Glioblastoma","Nimotuzumab","Inclusion Criteria:\n\n* 1）Aged 18 to 75 years.\n* 2）Newly diagnosed glioblastoma consistent with the World Health Organization (WHO) Classification of Tumours of the Central Nervous System, 5th edition.\n* 3）Epidermal growth factor receptor (EGFR)-positive status confirmed by immunohistochemistry (defined as brown-yellow staining in \\>10% of tumor cells).\n* 4）Partial surgical resection with radiographically measurable residual tumor.\n* 5）Karnofsky Performance Status (KPS) score ≥ 50% (with KPS decline attributable to the tumor).\n* 6）Adequate renal function, defined as serum creatinine ≤ 1.5 times the upper limit of normal (ULN) or creatinine clearance \\> 60 mL\u002Fmin.\n* 7）Adequate hepatic function, defined as total bilirubin ≤ 1.5 times the ULN and serum transaminases ≤ 3 times the ULN.\n* 8）Adequate hematologic function, defined as a white blood cell count ≥ 3,000\u002FμL or an absolute neutrophil count (ANC) ≥ 1,500\u002FμL, platelet count ≥ 100,000\u002FμL, and hemoglobin ≥ 10 g\u002FdL.\n* 9）An interval of 2 to 6 weeks between surgical resection and the initiation of radiotherapy (RT).\n\nExclusion Criteria:\n\n* 1）EGFR-negative status.\n* 2）Prior treatment with chemotherapy, anti-EGFR therapy, or radiotherapy; or a history of other malignancies within the past 5 years.\n* 3）Presence of severe comorbidities or active infections, or persistent vomiting that may interfere with the oral administration of temozolomide (TMZ).","75 Years",{"count":81,"type":21},50,[24],"This is a prospective, single-arm study. The study population consists of adult patients with a confirmed diagnosis of EGFR-positive high-grade glioma who have radiographic residual tumor following surgical resection. Participants will receive nimotuzumab in combination with the standard Stupp regimen after glioma surgery.",[85],"Glioma, Malignant","2026-07-12",{"date":88,"type":39},"2026-07-16",{"date":90,"type":21},"2026-07-03",{"date":92,"type":21},"2029-06-03",{"name":45,"class":46},{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":22,"phases":103,"briefSummary":104,"conditions":105,"keywords":107,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":47},"100645911","phase-2-yh02-injection-for-intra-tumor-injection-therapy-in-advanced-solid-tumors-with-unresponsive-or-failure-treated-cases-100645911","NCT07697937","YH02 Injection for Intra-tumor Injection Therapy in Advanced Solid Tumors With Unresponsive or Failure-Treated Cases","Clinical Study of YH02 Injection for Intra-tumor Injection Therapy in Advanced Solid Tumors With Unresponsive or Failure-Treated Cases","YH02","Inclusion Criteria:\n\n* Age: ≥18 years.\n* Resectable malignant solid tumors confirmed by histology or cytology (including head and neck cancer, breast cancer, melanoma, cervical cancer, skin malignancies, salivary gland carcinoma, oropharyngeal carcinoma, etc.) should prioritize treatment options for head and neck cancer, breast cancer, and melanoma.\n* After complete failure of standard treatment (disease progression or intolerance to therapy) and in the absence of effective therapeutic options.\n* There must be at least one measurable lesion (according to the RECIST 1.1 criteria), and the lesion must be suitable for intratumoral injection.\n* ECOG score ≤2.\n* The expected survival period is ≥12 weeks.\n* The subject must demonstrate adequate hematological and organ function, with all laboratory parameters evaluated within 7 days prior to the initial administration and meeting the following criteria: Hematologic system (no recent transfusion or hematopoietic stimulation therapy within 14 days): ANC ≥ 1.5 × 10⁹\u002FL; PLT ≥ 80 × 10⁹\u002FL; Hemoglobin (Hb) ≥ 85 g\u002FL; Liver function: Total bilirubin (TBIL) ≤ 2 × upper limit of normal (ULN) (≤ 3.0 × ULN for patients with Gilbert syndrome or liver metastases\u002Fhepatocellular carcinoma); Alanine aminotransferase (ALT) ≤ 2.5 × ULN; For patients with liver metastases or hepatocellular carcinoma: ALT ≤ 5 × ULN; Aspartate aminotransferase (AST) ≤ 2.5 × ULN; Albumin ≥ 2.8 g\u002FdL; Renal function: Creatinine ≤ 1.5 × ULN; or Creatinine clearance (Ccr) ≥ 30 mL\u002Fmin (calculated using the Cockcroft-Gault formula, only when creatinine\\> 1.5 × ULN); Coagulation function: Activated partial thromboplastin time (APTT) ≤ 1.5 × ULN; International normalized ratio (INR) or Prothrombin time (PT) ≤ 1.5 × ULN.\n* The subject has voluntarily signed an informed consent form and demonstrates good compliance.\n\nExclusion Criteria:\n\n* Patients had received antitumor therapy for the first time within 4 weeks prior to initial administration, including endocrine therapy, chemotherapy, radiotherapy, targeted therapy, immunotherapy, or traditional Chinese medicine-based antitumor treatment; or had participated in other clinical trials within 4 weeks before enrollment.\n\nDevelopment of any other malignant tumor other than the study tumor within 5 years prior to first use of the investigational drug, excluding locally advanced cancers that have been completely cured or are disease-free for at least 5 consecutive years, such as basal or squamous cell skin cancer, superficial bladder cancer, prostate carcinoma in situ, cervical carcinoma in situ, or breast ductal carcinoma in situ.\n\n* The adverse effects of previous antitumor treatments have not yet been classified as Grade ≤1 on the NCI CTCAE v5.0 grading scale (excluding toxicities such as alopecia and grade 2 neurotoxicity induced by prior platinum-based therapy, which researchers consider to pose no safety risks).\n* Receiving systemic glucocorticoids (prednisone\\>10 mg\u002Fday or equivalent doses of similar agents) or other immunosuppressive therapies within 2 weeks prior to initial use of the study drug, excluding the following: topical, ocular, intra-articular, intranasal, or inhaled glucocorticoid therapy; short-term (≤1 week) prophylactic use of glucocorticoids (e.g., for contrast agent allergy) or for treatment of non-autoimmune diseases (e.g., delayed hypersensitivity reactions induced by contact allergens).\n* Immuno-modulatory drugs, including but not limited to thymosin, IL-2, and interferon (IFN), were administered within 2 weeks prior to the first administration of the study drug.\n* A syndrome characterized by clinically significant autoimmune diseases (excluding well-controlled hypothyroidism). Patients with vitiligo, type 1 diabetes mellitus, or psoriasis who do not require systemic treatment and have no history of recurrence in the absence of external triggers are eligible for inclusion.\n* A live attenuated vaccine was administered within 4 weeks prior to the first use of the study drug.\n* Has previously received oncolytic virus therapy or other gene-based therapies.\n* Patients had undergone major surgical procedures or suffered severe trauma within 4 weeks prior to enrollment, or were expected to undergo significant surgery during the study period; furthermore, before the first administration of the investigational drug, all adverse events (AEs) related to surgery or major trauma had not resolved to CTCAE level ≤1 or baseline levels.\n* Patients with clinical manifestations of CNS metastasis or meningeal metastasis, or other evidence indicating that the patient's CNS or meningeal metastatic lesions are not under control, shall be deemed unsuitable for enrollment by the investigator. Patients with clinical symptoms suggestive of brain or meningeal disease require computed tomography (CT) or magnetic resonance imaging (MRI) examination.\n* For patients with previously treated brain metastases, inclusion may be considered if their clinical condition is stable within 4 weeks prior to enrollment, there is no evidence of new lesions or lesion progression, and they have not received glucocorticoid therapy within 1 week before the first administration.\n* Has a medical history of leptomeningitis.\n* Patients with a history or evidence of high-risk cardiovascular disease are eligible, including but not limited to: severe cardiac rhythm or conduction abnormalities (e.g., ventricular arrhythmias requiring clinical intervention, grade II-III atrioventricular block), a Fridericia formula-corrected QT interval (QTcF) ≥ 470 msec; acute coronary syndrome (including acute myocardial infarction and unstable angina), stroke, or other grade 3 or higher cardiovascular events occurring within 6 months prior to first administration; stent implantation within 6 months before initial use of the study drug; congestive heart failure classified as grade ≥ II according to the New York Heart Association (NYHA) criteria; echocardiographic findings of valvular morphological abnormalities (grade ≥ 2); note: patients with grade 1 valvular morphological abnormalities (e.g., mild regurgitation\u002Fstenosis) may be enrolled, but those with moderate valve thickening are excluded; left ventricular ejection fraction (LVEF) \\\u003Cthe institutional lower limit (or LVEF \\\u003C50% if no such limit exists); or poorly controlled blood pressure despite antihypertensive therapy (i.e., systolic blood pressure ≥ 160 mm Hg and\u002For diastolic blood pressure ≥ 100 mm Hg).\n* Virological tests: Positive for hepatitis B virus surface antigen (HBsAg); positive for hepatitis B core antibody (HBcAb) with hepatitis B virus (HBV) DNA level\\> upper limit of detection (ULN); positive for hepatitis C virus antibody (HCV-Ab) with hepatitis C virus (HCV) RNA level\\> ULN; positive for anti-human immunodeficiency virus antibody (Anti-HIV). Meeting any of the above criteria.\n* Had an active infection requiring systemic treatment (intravenous administration) within 2 weeks prior to the first use of the investigational drug, excluding local treatments.\n\nPatients known to have allergic reactions to any component of the YH02 injection formulation.\n\n* Individuals with known mental disorders that may affect research compliance or substance abuse.\n* Patients who have undergone or plan to undergo organ transplantation (e.g., liver transplantation).\n* Patients who, according to the investigators' assessment, have other severe systemic diseases, abnormal laboratory findings, or other reasons that make them unsuitable for participation in this clinical study.",{"count":81,"type":21},[24],"The preclinical pharmacological mechanism of YH02 injection is well established. By constructing a vector expressing MMP13, introducing a human S promoter, and genetically modifying the capsid protein, the virus's permeability, tumor targeting capability, and infection efficiency were significantly enhanced. Preclinical pharmacodynamic studies demonstrated that YH02 exhibits potent tumor growth inhibitory effects in various human-and murine-derived solid tumor models (including breast cancer, liver cancer, and melanoma). Given that oncolytic virus therapies already have approved products with demonstrated safety and efficacy worldwide, this study may offer potential clinical benefits for patients with advanced solid tumors who have failed standard treatments.\n\nYH02 injection has undergone an open-label, dose-escalating, and expanded Phase I clinical study in China aimed at evaluating the safety, tolerability, biodistribution characteristics, viral clearance, and immunogenicity of intratumoral administration of YH02 injection in patients with advanced solid tumors who have failed adequate standard therapy and lack effective treatment options, while preliminarily investigating its efficacy. No high-grade adverse drug reactions (ADRs) have been observed to date, nor were there any serious adverse events (SAEs), severe adverse drug reactions (SUSARs), or fatal events. The clinical safety and tolerability of this product for intratumoral administration are favorable.",[106],"Advanced Malignant Solid Tumor",[108,109,110,111],"advanced solid tumors","oncolytic virus","adenovirus","intratumor","2026-07-07",{"date":114,"type":39},"2026-07-13",{"date":116,"type":39},"2026-06-23",{"date":118,"type":21},"2028-07-31",{"name":45,"class":46},{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":130,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":47},"100641931","effect-of-liposomal-bupivacaine-tapb-combined-with-oxycodone-pcia-on-postoperative-gastrointestinal-recovery-in-patients-undergoing-major-abdominal-surgery-100641931","NCT07651722","Effect of Liposomal Bupivacaine TAPB Combined With Oxycodone PCIA on Postoperative Gastrointestinal Recovery in Patients Undergoing Major Abdominal Surgery","Effect of Liposomal Bupivacaine TAPB Combined With Oxycodone PCIA on Postoperative Gastrointestinal Function in Patients Undergoing Major Abdominal Surgery: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients scheduled to undergo elective major abdominal surgery, specifically small bowel or colorectal resections.\n* Aged between 18 and 80 years (inclusive).\n* American Society of Anesthesiologists (ASA) physical status I, II, or III.\n* Capable of understanding the study procedures, cooperating with postoperative pain\u002Frecovery assessments (e.g., VAS, QoR-15, I-FEED), and providing written informed consent prior to surgery.\n\nExclusion Criteria:\n\n* History of significant neuropsychiatric disorders, including schizophrenia, epilepsy, Parkinson's disease, or myasthenia gravis, that may interfere with pain perception or cognitive evaluation.\n* History of alcohol abuse or chronic opioid\u002Fanalgesic dependence.\n* Severe, uncontrolled hypertension (defined as systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg).\n* Severe cardiac, hepatic, renal, or pulmonary dysfunction that poses a high surgical\u002Fanesthetic risk or alters drug metabolism.\n* Pregnant or lactating women.\n* Known allergy, hypersensitivity, or contraindications to any of the study medications, including local anesthetics (ropivacaine, bupivacaine) or opioids (sufentanil, oxycodone).","80 Years",{"count":129,"type":21},132,[58],"Rationale and Objective:\n\nThe purpose of this study is to evaluate the clinical efficacy and safety of a novel multimodal analgesia regimen, combining transversus abdominis plane block (TAPB) with patient-controlled intravenous analgesia (PCIA), in improving postoperative gastrointestinal function recovery in patients undergoing major abdominal surgery.\n\nStudy Design and Interventions:\n\nThis is a prospective, single-center, randomized, double-blind, parallel-controlled trial. A total of 132 eligible patients (aged 18-80 years, ASA I-III, scheduled for elective small bowel or colorectal surgery) will be randomly allocated to one of three groups (n = 44 per group) to receive distinct postoperative analgesia regimens:\n\nGroup R-S: 0.375% Ropivacaine TAPB + Sufentanil PCIA; Group LB-S: 266 mg Liposomal Bupivacaine TAPB + Sufentanil PCIA; Group LB-O: 266 mg Liposomal Bupivacaine TAPB + Oxycodone PCIA.\n\nPrimary Outcome:\n\nThe primary outcome is the area under the curve (AUC) of the I-FEED scoring system within the first 7 postoperative days, which comprehensively reflects the overall trajectory of gastrointestinal function recovery.\n\nHypothesis:\n\nThe investigators hypothesize that the combination of long-acting Liposomal Bupivacaine TAPB (for prolonged somatic pain relief) and Oxycodone PCIA (for precise visceral pain control via dual u and k receptor agonism) will synergistically attenuate the perioperative stress-inflammatory response. Consequently, this regimen is expected to significantly mitigate postoperative ileus (POI) and accelerate the recovery of gastrointestinal motility",[133,134],"Postoperative Pain","Postoperative Ileus","2026-06-22",{"date":137,"type":39},"2026-06-25",{"date":139,"type":39},"2026-06-16",{"date":141,"type":21},"2026-09",{"name":45,"class":46},{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":150,"enrollmentInfo":151,"targetDuration":4,"studyType":22,"phases":153,"briefSummary":154,"conditions":155,"keywords":157,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":47},"100638657","efficacy-of-liposomal-bupivacaine-for-transversus-abdominis-plane-block-100638657","NCT07577934","Efficacy of Liposomal Bupivacaine for Transversus Abdominis Plane Block","Liposomal Bupivacaine Versus Ropivacaine for Transversus Abdominis Plane Block in Laparoscopic Cholecystectomy: A Randomized, Single-Blind, Parallel-Group Trial","Inclusion Criteria:\n\n* Age 18-65 years, either gender.\n* Patients scheduled for elective laparoscopic cholecystectomy.\n* ASA physical status I-III.\n* Able to provide written informed consent and complete the 3-month follow-up.\n\nExclusion Criteria:\n\n* History of allergy to local anesthetics.\n* History of dementia, psychosis, or other central nervous system diseases.\n* History of chronic pain or long-term use of opioids or other analgesics.\n* Contraindications to nerve block: infection at puncture site, severe coagulopathy.\n* Severe hepatic or renal dysfunction, pregnancy, or lactation.","65 Years",{"count":152,"type":21},86,[58],"This is a single-center, randomized, single-blind, parallel-group clinical trial. The study aims to compare the analgesic efficacy of liposomal bupivacaine versus ropivacaine for transversus abdominis plane (TAP) block in patients undergoing laparoscopic cholecystectomy. Eligible participants will be randomly assigned to receive either liposomal bupivacaine or ropivacaine for TAP block during surgery. The primary outcome is the dynamic NRS pain score at 24 hours after surgery. Secondary outcomes include static and dynamic NRS pain scores at multiple time points, QoR-15 recovery quality, time to first rescue analgesia, analgesic consumption, gastrointestinal function recovery, length of hospital stay, and adverse events. Participants will be followed up to 3 months after surgery to evaluate the incidence of chronic post-surgical pain (CPSP). All participants will receive routine clinical care, and participation is voluntary.",[133,156],"Liposomal Bupivacaine",[156,133,158,159],"Transverse Abdominal Plane Block","Anesthetic Recovery","2026-05-11",{"date":162,"type":39},"2026-05-14",{"date":164,"type":39},"2026-05-10",{"date":166,"type":21},"2026-08-01",{"name":45,"class":46},{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":127,"enrollmentInfo":174,"targetDuration":4,"studyType":176,"phases":4,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":185,"leadSponsor":187,"locationsCount":4},"100606260","a-real-world-study-of-adebrelimab-based-combination-regimens-in-the-treatment-of-advanced-solid-tumors-100606260","NCT07173244","A Real-world Study of Adebrelimab-based Combination Regimens in the Treatment of Advanced Solid Tumors","Inclusion Criteria:\n\n1. Signed informed consent and voluntarily enrolled in this study;\n2. Histologically or cytologically confirmed extensive-stage small cell lung cancer;\n3. Patients with other types of advanced solid tumors confirmed by histology or cytology; patients who, based on currently available data, the investigator believes may benefit from adebrelimab treatment may also be considered for enrollment;\n4. Patients in Cohort 1 who experience disease progression and whose second-line treatment options, as assessed by the investigator, include adebrelimab in combination therapy may be enrolled in Cohort 2;\n5. Age 18-80 years;\n6. Patients deemed by the investigator to be eligible for adebrelimab monotherapy or combination therapy;\n7. Female patients of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to the first dose of study drug (Cycle 1, Day 1). If the urine pregnancy test result cannot be confirmed as negative, a blood pregnancy test is required. Females and males of childbearing potential must agree to use appropriate contraceptive methods or undergo surgical sterilization during the trial and within 90 days after the last dose of the trial drug.\n8. Ability to comply with study and follow-up procedures.\n\nExclusion Criteria:\n\n1. Women who have been confirmed to be pregnant or breastfeeding;\n2. Patients with histologically or cytologically confirmed central nervous system tumors, urinary system tumors, reproductive system tumors, bone tumors, soft tissue sarcomas, melanomas and other skin tumors;\n3. Patients with a history of human immunodeficiency virus (HIV) infection (i.e. HIV 1\u002F2 antibody positive);\n4. Patients with known allergies to adebrelimab or any of its drugs and excipients;\n5. Patients who are deemed by the investigator to be unsuitable for participation in this study in any other circumstances, including but not limited to the following: (1) Patients with autoimmune diseases (AIDs), especially neurological AIDs, or AIDs that are moderate to severe or in active stage and cannot be controlled by immunosuppressants or require high-dose immunosuppressants to control symptoms; (2) Patients with tuberculosis infection, active tuberculosis, and suspected active TB should be examined by chest X-ray, sputum, and clinical symptoms and signs to exclude; (3) The patient has previously received or is about to receive solid organ transplantation or hematopoietic stem cell transplantation; (4) The patient needs to use large doses of antibiotics, glucocorticoids, proton pump inhibitors and other drugs for a long time.",{"count":175,"type":21},300,"OBSERVATIONAL","This prospective, multicenter, non-interventional, observational, real-world study was designed to evaluate the safety and efficacy of an adebrelimab-based regimen in patients with advanced solid tumors.",[179,27,180],"Non-Small Cell Lung Cancer","Gastrointestinal Cancers","2025-09-08",{"date":183,"type":39},"2025-09-15",{"date":183,"type":21},{"date":186,"type":21},"2029-09",{"name":45,"class":46},""]